
1644670-37-0 Iptacopan
CAS:1644670-37-0 MF:C25H30N2O4 MW:422.52 EINECS: MDL No.:MFCD32174282
Properties
Appearance Off-white to gray Solid
Boiling point:599.1±50.0 °C
Density 1.25±0.1 g/cm3
storage temp. Store at -20°C
solubility DMSO:50.0(Max Conc. mg/mL);118.34(Max Conc. mM)
pka4.07±0.10
Application:
Complement deposition is often seen in renal biopsy reports of patients with immunoglobulin A (IgA) nephropathy, so some scholars speculate that inhibiting complement can treat some IgA nephropathy patients. Iptacopan (LNP023) is a factor B inhibitor that has complement inhibitory effects. In previous clinical studies, compared to glucocorticoids, its impact on the immune and endocrine systems was relatively small, and the risk of serious adverse events was relatively low. It may be used to treat IgA nephropathy.
Synonyms:
Iptacopan
1644670-37-0
LNP023
LNP-023
NVP-LNP023
NVP-LNP023-NX
4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid
Benzoic acid, 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]-
FABHALTA
LNP 023
Benzoic acid, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-2-piperidinyl)-
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid
4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid
iptacopanum
4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid
Factor B Inhibitor LNP023
GTPL10710
LNP023
Hot Tags: 1644670-37-0 iptacopan, China 1644670-37-0 iptacopan manufacturers, suppliers, api passwordless authentication api integration, api management platforms, Piracetam, api expense tracking api integration, Sulfaquinoxaline, api artificial intelligence powered api integration

